ASX

21.25

-2.43%↓

FROG

43.35

-1.81%↓

PII

55.87

-0.3%↓

NWL

3.52

-2.22%↓

BFLY.US

4.18

-0.95%↓

ASX

21.25

-2.43%↓

FROG

43.35

-1.81%↓

PII

55.87

-0.3%↓

NWL

3.52

-2.22%↓

BFLY.US

4.18

-0.95%↓

ASX

21.25

-2.43%↓

FROG

43.35

-1.81%↓

PII

55.87

-0.3%↓

NWL

3.52

-2.22%↓

BFLY.US

4.18

-0.95%↓

ASX

21.25

-2.43%↓

FROG

43.35

-1.81%↓

PII

55.87

-0.3%↓

NWL

3.52

-2.22%↓

BFLY.US

4.18

-0.95%↓

ASX

21.25

-2.43%↓

FROG

43.35

-1.81%↓

PII

55.87

-0.3%↓

NWL

3.52

-2.22%↓

BFLY.US

4.18

-0.95%↓

Search

Diversified Healthcare Trust

Ouvert

SecteurIndices

6.65 -3.06

Résumé

Variation du prix de l'action

24h

Actuel

Min

6.47

Max

6.9399999999999995

Chiffres clés

By Trading Economics

Revenu

143M

-21M

Ventes

-9.1M

380M

BPA

-0.063

Rendement du dividende

0.55

Marge bénéficiaire

-5.591

EBITDA

190M

136M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+8.05% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.55%

3.19%

Prochains Résultats

4 mai 2026

Date du Prochain Dividende

14 mai 2026

Date du Prochain Détachement de Dividende

21 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

278M

1.8B

Ouverture précédente

9.71

Clôture précédente

6.65

Sentiment de l'Actualité

By Acuity

43%

57%

6 / 26 Classement par Indices

Score Technique

By Trading Central

Confiance

Bullish Evidence

Diversified Healthcare Trust Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 mars 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mars 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mars 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mars 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mars 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mars 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mars 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mars 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mars 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mars 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mars 2026, 22:18 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mars 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mars 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mars 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mars 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mars 2026, 21:10 UTC

Principaux Événements d'Actualité

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mars 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk
Résultats
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Diversified Healthcare Trust prévision

Objectif de Prix

By TipRanks

8.05% hausse

Prévisions sur 12 Mois

Moyen 7.25 USD  8.05%

Haut 8.5 USD

Bas 6 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

2.34 / 3.02Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

6 / 26Classement par Indices

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Diversified Healthcare Trust

DHC is a real estate investment trust, or REIT, focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum by care delivery and practice type, by scientific research disciplines and by property type and location. As of December 31, 2023, DHC's approximately $7.2 billion portfolio included 371 properties in 36 states and Washington, D.C., occupied by approximately 500 tenants, and totaling approximately 8.6 million square feet of life science and medical office properties and more than 27,000 senior living units. DHC is managed by The RMR Group (Nasdaq: RMR), a leading U.S. alternative asset management company with over $41 billion in assets under management as of December 31, 2023 and more than 35 years of institutional experience in buying, selling, financing and operating commercial real estate. DHC is headquartered in Newton, MA.
help-icon Live chat